These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 27785421)

  • 1. Lynch syndrome and exposure to aristolochic acid in upper-tract urothelial carcinoma: its clinical impact?
    Colin P; Seisen T; Mathieu R; Shariat SF; Rouprêt M
    Transl Androl Urol; 2016 Oct; 5(5):648-654. PubMed ID: 27785421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Epidemiology and risk factors of upper urinary tract tumors: literature review for the yearly scientific report of the French National Association of Urology].
    Ouzzane A; Rouprêt M; Leon P; Yates DR; Colin P
    Prog Urol; 2014 Nov; 24(15):966-76. PubMed ID: 25158329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular aspects of upper tract urothelial carcinoma.
    Patel N; Arya M; Muneer A; Powles T; Sullivan M; Hines J; Kelly J
    Urol Oncol; 2014 Jan; 32(1):28.e11-20. PubMed ID: 23428541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Upper Tract Urothelial Carcinoma in the Lynch Syndrome Tumour Spectrum: A Comprehensive Overview from the European Association of Urology - Young Academic Urologists and the Global Society of Rare Genitourinary Tumors.
    Lonati C; Necchi A; Gómez Rivas J; Afferi L; Laukhtina E; Martini A; Ventimiglia E; Colombo R; Gandaglia G; Salonia A; Briganti A; Montorsi F; Mattei A; Simeone C; Carlo MI; Shariat SF; Spiess PE; Moschini M;
    Eur Urol Oncol; 2022 Feb; 5(1):30-41. PubMed ID: 34896051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aristolochic acid-associated urinary tract cancers: an updated meta-analysis of risk and oncologic outcomes after surgery and systematic review of molecular alterations observed in human studies.
    Kang YC; Chen MH; Lin CY; Lin CY; Chen YT
    Ther Adv Drug Saf; 2021; 12():2042098621997727. PubMed ID: 33815744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Universal Lynch Syndrome Screening Should be Performed in All Upper Tract Urothelial Carcinomas.
    Ju JY; Mills AM; Mahadevan MS; Fan J; Culp SH; Thomas MH; Cathro HP
    Am J Surg Pathol; 2018 Nov; 42(11):1549-1555. PubMed ID: 30148743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patients with Lynch syndrome mismatch repair gene mutations are at higher risk for not only upper tract urothelial cancer but also bladder cancer.
    Skeldon SC; Semotiuk K; Aronson M; Holter S; Gallinger S; Pollett A; Kuk C; van Rhijn B; Bostrom P; Cohen Z; Fleshner NE; Jewett MA; Hanna S; Shariat SF; Van Der Kwast TH; Evans A; Catto J; Bapat B; Zlotta AR
    Eur Urol; 2013 Feb; 63(2):379-85. PubMed ID: 22883484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Balkan Endemic Nephropathy and the Causative Role of Aristolochic Acid.
    Jelaković B; Dika Ž; Arlt VM; Stiborova M; Pavlović NM; Nikolić J; Colet JM; Vanherweghem JL; Nortier JL
    Semin Nephrol; 2019 May; 39(3):284-296. PubMed ID: 31054628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aristolochic acid-containing Chinese herbal medicine and upper urinary tract urothelial carcinoma in Taiwan: a narrative review.
    Dickman KG; Chen CH; Grollman AP; Pu YS
    World J Urol; 2023 Apr; 41(4):899-907. PubMed ID: 35867141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Carcinogenic pathways and natural history of upper tract urothelial carcinomas: state-of-the-art review for the yearly scientific report of the French National Association of Urology].
    Seisen T; Cancel-Tassin G; Colin P; Cussenot O; Rouprêt M
    Prog Urol; 2014 Nov; 24(15):943-53. PubMed ID: 25158326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A proportion of hereditary upper urinary tract urothelial carcinomas are misclassified as sporadic according to a multi-institutional database analysis: proposal of patient-specific risk identification tool.
    Audenet F; Colin P; Yates DR; Ouzzane A; Pignot G; Long JA; Soulie M; Phé V; Bensadoun H; Guy L; Ruffion A; Valeri A; Cormier L; Droupy S; de La Taille A; Saint F; Faïs PO; Houlgatte A; Cussenot O; Rouprêt M;
    BJU Int; 2012 Dec; 110(11 Pt B):E583-9. PubMed ID: 22703159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genitourinary manifestations of Lynch syndrome in the urological practice.
    Lonati C; Simeone C; Suardi N; Spiess PE; Necchi A; Moschini M
    Asian J Urol; 2022 Oct; 9(4):443-450. PubMed ID: 36381590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular profiles and urinary biomarkers of upper tract urothelial carcinomas associated with aristolochic acid exposure.
    Karanović S; Ardin M; Tang Z; Tomić K; Villar S; Renard C; Venturini E; Lorch AH; Lee DS; Stipančić Ž; Slade N; Vuković Brinar I; Dittrich D; Karlović K; Borovečki F; Dickman KG; Olivier M; Grollman AP; Jelaković B; Zavadil J
    Int J Cancer; 2022 Jan; 150(2):374-386. PubMed ID: 34569060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update.
    Rouprêt M; Babjuk M; Compérat E; Zigeuner R; Sylvester RJ; Burger M; Cowan NC; Böhle A; Van Rhijn BW; Kaasinen E; Palou J; Shariat SF
    Eur Urol; 2015 Nov; 68(5):868-79. PubMed ID: 26188393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Upper urinary tract urothelial cell carcinomas and other urological malignancies involved in the hereditary nonpolyposis colorectal cancer (lynch syndrome) tumor spectrum.
    Rouprêt M; Yates DR; Comperat E; Cussenot O
    Eur Urol; 2008 Dec; 54(6):1226-36. PubMed ID: 18715695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of Lynch syndrome among patients with upper urinary tract carcinoma in a Japanese hospital-based population.
    Ito T; Kono K; Eguchi H; Okazaki Y; Yamamoto G; Tachikawa T; Akagi K; Okada Y; Kawakami S; Morozumi M; Tamaru JI; Ishida H
    Jpn J Clin Oncol; 2020 Jan; 50(1):80-88. PubMed ID: 31665498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aristolochic acid mutational signature defines the low-risk subtype in upper tract urothelial carcinoma.
    Lu H; Liang Y; Guan B; Shi Y; Gong Y; Li J; Kong W; Liu J; Fang D; Liu L; He Q; Shakeel M; Li X; Zhou L; Ci W
    Theranostics; 2020; 10(10):4323-4333. PubMed ID: 32292497
    [No Abstract]   [Full Text] [Related]  

  • 18. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2017 Update.
    Rouprêt M; Babjuk M; Compérat E; Zigeuner R; Sylvester RJ; Burger M; Cowan NC; Gontero P; Van Rhijn BWG; Mostafid AH; Palou J; Shariat SF
    Eur Urol; 2018 Jan; 73(1):111-122. PubMed ID: 28867446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomic Characterization of Upper-Tract Urothelial Carcinoma in Patients With Lynch Syndrome.
    Donahue TF; Bagrodia A; Audenet F; Donoghue MTA; Cha EK; Sfakianos JP; Sperling D; Al-Ahmadie H; Clendenning M; Rosty C; Buchanan DD; Jenkins M; Hopper J; Winship I; Templeton AS; Walsh MF; Stadler ZK; Iyer G; Taylor B; Coleman J; Lindor NM; Solit DB; Bochner BH
    JCO Precis Oncol; 2018; 2018():. PubMed ID: 30854504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Upper urinary tract disease: what we know today and unmet needs.
    Mathieu R; Bensalah K; Lucca I; Mbeutcha A; Rouprêt M; Shariat SF
    Transl Androl Urol; 2015 Jun; 4(3):261-72. PubMed ID: 26816829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.